Search research articles
Contact Us
Filters
Showing results (11-20 of 59) with videos related to
Page
of 6
Sort By:
Rheumatology (Oxford, England)
|
April 19, 2022
Challenging wisely: how to move beyond '1 mg/kg then taper'
Shannon Tai, Natalie Anumolu, Michael Putman
Rheumatology (Oxford, England)
|
September 4, 2023
Advocating for better trials in rheumatology
Sharanya Kaushik, Mats Junek, Michael Putman
The Lancet. Rheumatology
|
January 22, 2024
Unintentional unblinding in rheumatic disease trials
Cody Bruggemeyer, Desh Nepal, Michael Putman
Rheumatology (Oxford, England)
|
July 8, 2023
Twenty-five years of novel drug approvals in rheumatology
Kathryn Henry, Natalie Anumolu, Michael Putman
Journal of Immunological Methods
|
July 9, 2005
Simplified method to automatically count bacterial colony forming unit
Michael Putman, Robert Burton, Moon H Nahm
Rheumatology (Oxford, England)
|
May 13, 2022
There is no diagnosis of exclusion in rheumatology
Michael Putman, Jayshil J Patel, Anisha Dua
Current Opinion in Rheumatology
|
July 18, 2020
Tracking clinical resources for coronavirus disease 2019
Garret Duron, Lauren Gelman, Anisha Dua, et al.
The Lancet. Rheumatology
|
January 22, 2024
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study
Shikha Singla, Michael Putman, Jean Liew, et al.
The Lancet. Rheumatology
|
January 22, 2024
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply
Shikha Singla, Michael Putman, Jean Liew, et al.
Clinical Rheumatology
|
March 20, 2026
Increased apathy level in systemic lupus erythematosus
Natalie M Anumolu, Michael Putman, David J Gazeley
Page
of 6
Search research articles
Search
Showing results (11-20 of 59) with videos related to
Sort By:
Page
of 6
Rheumatology (Oxford, England)
|
April 19, 2022
Challenging wisely: how to move beyond '1 mg/kg then taper'
Shannon Tai, Natalie Anumolu, Michael Putman
Rheumatology (Oxford, England)
|
September 4, 2023
Advocating for better trials in rheumatology
Sharanya Kaushik, Mats Junek, Michael Putman
The Lancet. Rheumatology
|
January 22, 2024
Unintentional unblinding in rheumatic disease trials
Cody Bruggemeyer, Desh Nepal, Michael Putman
Rheumatology (Oxford, England)
|
July 8, 2023
Twenty-five years of novel drug approvals in rheumatology
Kathryn Henry, Natalie Anumolu, Michael Putman
Journal of Immunological Methods
|
July 9, 2005
Simplified method to automatically count bacterial colony forming unit
Michael Putman, Robert Burton, Moon H Nahm
Rheumatology (Oxford, England)
|
May 13, 2022
There is no diagnosis of exclusion in rheumatology
Michael Putman, Jayshil J Patel, Anisha Dua
Current Opinion in Rheumatology
|
July 18, 2020
Tracking clinical resources for coronavirus disease 2019
Garret Duron, Lauren Gelman, Anisha Dua, et al.
The Lancet. Rheumatology
|
January 22, 2024
Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study
Shikha Singla, Michael Putman, Jean Liew, et al.
The Lancet. Rheumatology
|
January 22, 2024
Differentiating biologics to prevent psoriatic arthritis in patients with psoriasis - Authors' reply
Shikha Singla, Michael Putman, Jean Liew, et al.
Clinical Rheumatology
|
March 20, 2026
Increased apathy level in systemic lupus erythematosus
Natalie M Anumolu, Michael Putman, David J Gazeley
Page
of 6